Please assess the completion status of the following clinical trial:

Trial Title: DNA Vaccine for Ragweed Allergic Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women 18 to 60 years of age;~* Who provide informed consent;~* Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy;~* Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge;~* Are in general good health; and are available for the duration of the study.~Exclusion Criteria:~* Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded.~* Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).